130656-51-8

Basic information

• Product Name: Nifekalant hydrochloride
• Synonyms: Nifekalant 130636-43-0 /;1,3-Dimethyl-6-[2-(N-(2-hydroxyethyl)-3-(4-nitrophenyl)propylamino)ethylamino]-2,4(1H,3H)-pyrimidinedione hydrochloride;1,3-Dimethyl-6-((2-(N-(2-hydroxyethyl)-3-(4-nitrophenyl)propylamino)ethylamino)-2,4(1H),3H)-pyrimidinedione HCl;2,4(1H,3H)-Pyrimidinedione, 6-((2-((2-hydroxyethyl)(3-(4-nitrophenyl)propyl)amino)ethyl)amino)-1,3-dimethyl-, monohydrochloride;6-[[2-[(2-Hydroxyethyl)[3-(4-nitrophenyl)propyl]aMino]ethyl]aMino]-1,3-diMethyl-2,4(1H,3H)-pyriMidinedione Hydrochloride;Shinbit;ms551;NIFEKALANT HYDROCHLORIDE
• CAS NO: 130656-51-8
• Molecular Formula: C₁₉H₂₇N₅O₅*ClH
• Molecular Weight: 441.91
• EINECS: 1533716-785-6
• Product Categories: Amines;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Inhibitors
• Mol File: 130656-51-8.mol
• Article Data: 1

Chemical Properties

• Melting Point: 172-174°
• Boiling Point: 597.9 °C at 760 mmHg
• Flash Point: 315.4 °C
• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly, Heated), Methanol (Slightly, Heated), Water (Slightly)
• PKA: 7.05(at 25℃)
• CAS DataBase Reference: Nifekalant hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Nifekalant hydrochloride(130656-51-8)
• EPA Substance Registry System: Nifekalant hydrochloride(130656-51-8)

Safety Data

• Hazardous Substances Data: 130656-51-8(Hazardous Substances Data)

Usage

Description

Nifekalant hydrochloride, also known as Shinbit, is a novel and pure class III anti-arrhythmic agent that was introduced in Japan for the treatment of serious ventricular arrhythmias. It is a non-selective blocker of myocardial repolarizing potassium currents and lacks any β-adrenergic blocking effect. Nifekalant hydrochloride is a yellow solid and has been shown to significantly prolong action potential duration, atrial and ventricular refractory periods in various studies. It also inhibits the human multidrug and toxin extrusion (MATE) transporter 1 (MATE1).

Uses

Used in Cardiology:
Nifekalant hydrochloride is used as an antiarrhythmic agent for the treatment of patients with extensive anterior infarction and severe ventricular dysfunction. It is particularly beneficial in initial resuscitation after cardiac arrest, as demonstrated in clinical trials. The specific characteristics of its voltageand time-dependent K+ current blockade might differentiate Nifekalant from other class III agents currently in use.
Used in Pharmaceutical Research:
Nifekalant hydrochloride is used as a research compound for studying the effects of class III anti-arrhythmic agents on cardiac electrophysiology and the development of new treatments for arrhythmias. Its unique properties, such as blocking the rapidly activating delayed rectifier potassium channel (IKr) and inhibiting the human MATE1 transporter, make it a valuable tool in understanding the underlying mechanisms of arrhythmias and potential therapeutic targets.

Originator

Mitsui (Japan)

InChI:InChI=1/C19H27N5O5.ClH/c1-21-17(14-18(26)22(2)19(21)27)20-9-11-23(12-13-25)10-3-4-15-5-7-16(8-6-15)24(28)29;/h5-8,14,20,25H,3-4,9-13H2,1-2H3;1H

Upstream product

• 20716-25-0 3-(4-nitrophenyl)-1-propanol 
• 130636-43-0 1,3-dimethyl-6-[2-(N-[2-hydroxyethyl]-3-[4-nitrophenyl]propylamino)ethylamino]-2,4(1H,3H)-pyrimidinedione 
• 5770-44-5 6-(2-hydroxyethylamino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dion 
• 6642-31-5 6-Amino-1,3-dimethylbarbituric acid 
• 130634-04-7 1,3-dimethyl-6-[2-(p-toluenesulfonyloxy)ethylamino)-2,4(1H,3H)-pyrimidinedione 

Relevant articles and documents

A method for preparing high-purity hydrochloric acid Nepal non-Kalland

The invention discloses a preparation method of nifekalant hydrochloride. The preparation method comprises the following steps of: performing aminolysis on 6-imino-1,3-dimethyluracil to obtain 1,3-dimethyl-6-(2-ethoxy)aminouracil; esterfying 1,3-dimethyl-